**Conflict of interests and source of funding**

The authors declare no competing financial interests. This study was supported in part by the National Natural Science Foundation of China (Nos. 81860489, 81760502, 81572353, and 81660495), the Natural Science Foundation of Guangxi (Nos. 2018GXNSFAA281043, 2017GXNSFAA198002, and 2017GXNSFGA198002), Research Program of Guangxi "Zhouyue Scholar" (No. 2017-38), Research Program of Guangxi Specially invited Expert (No. 2017-6th), the "12th Five" Planning Program of Guangxi Education Science (No. 2015C397), the Innovative Program of Guangxi Graduate Education (No. JGY2015139), Research Program of Guangxi Clinic Research Center of Hepatobiliary Diseases (No. AD17129025), and Open Research Program from Molecular Immunity Study Room Involving in Acute and Severe Diseases in Guangxi Colleges and Universities (Nos. kfkt20160062 and kfkt20160063).

**113**

**Author details**

Qin-Qin Long†

for Nationalities, Baise, China

*The Blood AFB1-DNA Adduct Acting as a Biomarker for Predicting the Risk and Prognosis…*


*DOI: http://dx.doi.org/10.5772/intechopen.88666*

AFB1-GA AFB1's 8,9-dihydro-8-(N7

HBsAg hepatitis B surface antigen

LAL low AFB1-DNA adduct level MAL medium AFB1-DNA adduct level

PHCC primary hepatocellular carcinoma

RFS tumor recurrence-free survival

, Xiao-Qin Wu†

\*Address all correspondence to: yyyaojg001@163.com

† These authors contributed equally to this work.

provided the original work is properly cited.

 and Jin-Guang Yao\* Department of Pathology, The Affiliated Hospital of Youjiang Medical University

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium,

HAL high AFB1-DNA adduct level

AFB1-FAPa AFB1-formamidopyrimidine adduct

**Abbreviations**

AFB1 Aflatoxin B1

HBV hepatitis B virus

HCV hepatitis C virus CI confidence interval HR hazard ratio

OR odds ratio

OS overall survival

*The Blood AFB1-DNA Adduct Acting as a Biomarker for Predicting the Risk and Prognosis… DOI: http://dx.doi.org/10.5772/intechopen.88666*
